APA (7th ed.) Citation

Gantner, P., Bani-Sadr, F., Garraffo, R., Roger, P., Treger, M., Jovelin, T., . . . cohort, D. (2016). Switch to Ritonavir-Boosted versus Unboosted Atazanavir plus Raltegravir Dual-Drug Therapy Leads to Similar Efficacy and Safety Outcomes in Clinical Practice. Public Library of Science (PLoS).

Chicago Style (17th ed.) Citation

Gantner, Pierre, Firouze Bani-Sadr, Rodolphe Garraffo, Pierre-Marie Roger, Michèle Treger, Thomas Jovelin, Pascal Pugliese, David Rey, and Dat’AIDS cohort. Switch to Ritonavir-Boosted Versus Unboosted Atazanavir Plus Raltegravir Dual-Drug Therapy Leads to Similar Efficacy and Safety Outcomes in Clinical Practice. Public Library of Science (PLoS), 2016.

MLA (9th ed.) Citation

Gantner, Pierre, et al. Switch to Ritonavir-Boosted Versus Unboosted Atazanavir Plus Raltegravir Dual-Drug Therapy Leads to Similar Efficacy and Safety Outcomes in Clinical Practice. Public Library of Science (PLoS), 2016.